Windlas Biotech Limited

WINDLAS

INE0H5O01029

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 08:01:54 18/05/2024 BST			5-day change	1st Jan Change
553.1 ^INR	+1.90%		+7.65%	+29.00%

04-02	Windlas Biotech Commissions New Injectible Manufacturing Unit	MT
04-02	Windlas Biotech Limited Commissions Its Injectable Facility	CI

Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.

May 03, 2023 at 05:35 pm

From April 1, 2023 to May 3, 2023, the company has repurchased 128,053 shares, representing 0.61% for INR 32.07 million. With this, the company has completed the repurchase of 995,800 shares, representing 4.6% for INR 250.04 million under the buyback announced on November 8, 2022.

Latest news about Windlas Biotech Limited

Windlas Biotech Commissions New Injectible Manufacturing Unit	04-02	MT
Windlas Biotech Limited Commissions Its Injectable Facility	04-02	CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Windlas Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23	12/09/23	CI
Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2022-23	18/08/23	CI
Windlas Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/08/23	CI
Windlas Biotech's Consolidated Profit Slips in Fiscal Q4	08/05/23	MT
Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023	05/05/23	CI
Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	05/05/23	CI
Windlas Biotech Limited Recommends Dividend	05/05/23	CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.	05/05/23	CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.	03/05/23	CI
Windlas Biotech Limited's Equity Buyback announced on November 8, 2022 has closed with 867,747 shares, representing 3.98% for INR 217.97 million.	02/05/23	CI
Windlas Biotech's Consolidated Profit Climbs in Fiscal Q3	09/02/23	MT
Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive Officer	09/02/23	CI
Windlas Biotech Appoints CEO	09/02/23	MT
Windlas Biotech Names New CEO	08/02/23	MT
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	08/02/23	CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022.	08/02/23	CI

Chart Windlas Biotech Limited

Duration

Period

More charts

Company Profile

Windlas Biotech Limited is an India-based company that is primarily engaged in the manufacturing and trading of pharmaceutical products. The Company provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Companyâs service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. It has capabilities for both solid and liquid pharmaceutical dosage forms. The Company markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. It also has a salesforce and distribution network spread across over 14 states. The Companyâs manufacturing facilities are located at Dehradun in Uttarakhand.

Sector

Pharmaceuticals

Calendar

19/05/2024 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
WINDLAS BIOTECH LIMITED	+29.00%	136M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B